VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO 2022 | ADCs for the treatment of HER2-low breast cancer

Paolo Tarantino, MD, Dana-Farber Cancer Institute, Boston, MA, reflects on the use of antibody-drug conjugates (ADCs) for the treatment of HER2-low breast cancer, including trastuzumab duocarmazine which was evaluated in the TULIP trial (NCT03262935), where it demonstrated activity in HER2-low patients, as well as disitamab vedotin which has shown similar response rates. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter